Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus.

ABSTRACT: Respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) are two closely related viruses that cause bronchiolitis and pneumonia in infants and the elderly¹, with a significant health burden^2-6. There are no licensed vaccines or small-molecule antiviral treatments specific to these two viruses at present. A humanized murine monoclonal antibody (palivizumab) is approved to treat high-risk infants for RSV infection^7,8, but other treatments, as well as vaccines, for both viruses are still in development. Recent epidemiological modelling suggests that cross-immunity between RSV, HMPV and human parainfluenzaviruses may contribute to their periodic outbreaks⁹, suggesting that a deeper understanding of host immunity to these viruses may lead to

SUBMITTER: Wen X 

PROVIDER: S-EPMC5308794 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature